Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 11/20 | 0.58 |
| ▸ | CA1 | P00915 | 10/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | ITGA1 | P56199 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | WDR5 | P61964 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2237044 | 0.80 | CA2 (0.75) | CA2CA1CA9MEN1KMT2A | |
| SCHEMBL13028571 | 0.78 | CA1 (0.57) | CA2CA1CA9CA7CA14 | |
| SCHEMBL2236215 | 0.77 | CDK1 (0.53) | CA2CA1CA9CA7PTGES2 | |
| SCHEMBL2237325 | 0.75 | CA2 (0.47) | CA2CA1MEN1KMT2APTGES2 | |
| SCHEMBL2308296 | 0.74 | CA2 (0.79) | CA2CA1CA9MEN1KMT2A | |
| SCHEMBL13552707 | 0.73 | CES1 (0.57) | CA2CA1CA9CA7CA14 | |
| SCHEMBL841673 | 0.73 | CA2 (0.51) | CA2CA1CA9CA7CA14 | |
| Methane SCHEMBL11683447 | 0.73 | MEN1 (0.59) | CA2CA1MEN1KMT2APGR | |
| SCHEMBL28513727 | 0.72 | HTR6 (0.55) | CA2CA1CA9CA7CA14 | |
| SCHEMBL11078586 | 0.72 | CA2 (0.49) | CA2CA1CA9CA7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2349990-B1 | ARYL-PHENYL-SULFONAMIDE-PHENYLENE COMPOUNDS AND THEIR USE | PIMCO 2664 LTD (GB) | 2018-05-02 | — | — | EP | disclosed |
| US-8207167-B2 | Aryl-phenyl-sulfonamide-phenylene compounds and their use | PIMCO 2664 LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-8207167-B2 | Aryl-phenyl-sulfonamide-phenylene compounds and their use | PIMCO 2664 LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-20110190302-A1 | Aryl-Phenyl-Sulfonamide-Phenylene Compounds and Their Use | PIMCO 2664 LIMITED (GB) | 2011-08-04 | — | — | US | disclosed |
| US-20110190302-A1 | Aryl-Phenyl-Sulfonamide-Phenylene Compounds and Their Use | PIMCO 2664 LIMITED (GB) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190302-A1 | Aryl-Phenyl-Sulfonamide-Phenylene Compounds and Their Use | SOST, PSAP, ARSA | CA2 2774/4885CA1 3022/4885CA9 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.